The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...

The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

The Swiss drug development company Windward Bio recently announced that it had officially launched with a $200 million Series ...

The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and commercialization of Regenxbio’s gene therapies RGX-121 for the treatment of ...